How Many Ketamine Treatments for Depression Do You Need?
Once someone has decided ketamine treatment is worth exploring for depression, the next question is almost always practical: how many sessions, how often, and for how long. There isn't a single number that applies to every patient, but there are well-established patterns most clinics and the FDA-approved Spravato label both follow — an initial induction series, followed by tapering maintenance dosing. This guide covers the protocol and scheduling side specifically: session counts, dosing cadence, how clinicians judge whether a series is working, and what a mid-series non-response means. For the separate question of whether ketamine actually works for depression and who tends to benefit, see the companion guide on does ketamine therapy work for depression.
The Typical IV Ketamine Induction Series
Most clinics offering IV ketamine infusions for depression start with an induction series of around six infusions delivered over two to three weeks — typically two to three sessions per week rather than daily dosing. That six-infusion pattern traces back to some of the earliest academic ketamine trials and remains the most commonly cited protocol in published research and clinic materials, but it's a common starting point, not a fixed rule every clinic follows exactly. Some providers run shorter series and reassess sooner; others extend to eight or more sessions for patients who show partial response but haven't plateaued. The number that matters is the one your specific clinic proposes based on your history and how you're responding, not a figure quoted online.
Spacing matters as much as the total count. Infusions are usually spread across the week rather than clustered, which gives the clinical team a chance to observe how each dose affects mood before the next one, and gives the patient time to notice whether benefits are building, holding steady, or fading between visits. Skipping or significantly delaying sessions within the induction series is generally discouraged, since the cumulative effect clinicians are aiming for depends on a reasonably consistent schedule — an infusion pushed back by a week or more can blunt the pattern a provider is trying to establish.
Spravato's Labeled Dosing Schedule
Spravato (esketamine) follows a fixed schedule set by its FDA label rather than one adjusted freely by individual clinics. Induction dosing is twice weekly for the first four weeks. From weeks five through eight, dosing typically steps down to once weekly. From week nine onward, patients move to a maintenance phase dosed weekly or every other week, depending on how they've responded. That structure means a full path from first dose to less-frequent maintenance dosing takes roughly two months — longer than a typical IV induction series, but built around a labeled protocol rather than session-by-session clinical judgment alone. A prescriber can still adjust maintenance frequency within that framework based on how symptoms hold between doses.
Because Spravato must be administered at a REMS-certified clinic with roughly two hours of post-dose observation each visit, the schedule also has a logistical dimension IV ketamine doesn't: twice-weekly visits for a month is a real time commitment, and it's worth planning around before starting rather than discovering partway through.
Ketamine Dosing for Depression: What Patients Should Know
Dosing decisions — the actual milligrams, infusion rate, or nasal-spray strength — sit with the prescribing clinician and depend on body weight, treatment format, and how a patient responds and tolerates side effects. This isn't something to work out from general information online, and a responsible clinic won't hand a patient a dosing chart to self-manage. What's useful to understand at a patient level is the shape of the process: IV ketamine doses are typically set and adjusted infusion to infusion based on response and tolerability, since the clinician controls the rate in real time. Spravato doses are fixed by the label — 56mg or 84mg — with the specific dose and any adjustment decided by the prescriber rather than titrated mid-session. Either way, the first one or two sessions of a series often function partly as a calibration period, where the clinical team is watching how you tolerate and respond before settling into a steady dose for the rest of the series.
IM (intramuscular) ketamine, sometimes offered as an alternative to an IV line, is usually scheduled on a similar induction cadence to IV ketamine — around six sessions over a comparable window — since the total drug exposure is comparable even though the delivery method differs. It gives a clinician less real-time control over the dose once it's injected, since there's no line to adjust mid-session the way there is with an infusion. Oral ketamine troches, more often dispensed through telehealth programs for at-home use, tend to follow a longer, lower-intensity schedule rather than a tight induction series, reflecting their generally lower peak dosing.
Maintenance and Booster Sessions
Finishing an induction series isn't the end of treatment for most patients — it's the point where the schedule shifts from building a response to sustaining one. Maintenance dosing for IV ketamine is typically spaced out much further than induction, commonly every few weeks to a few months, with the exact interval set by how long each treatment's relief lasts rather than a fixed calendar. Some patients need a booster every three to four weeks to stay stable; others go two months or longer between sessions. Spravato's maintenance phase is somewhat more structured by the label — weekly or every-other-week — but a prescriber still has room to adjust frequency based on symptom control.
There's no single point at which maintenance dosing is expected to end for everyone. Some patients taper off entirely after months of stability; others continue periodic booster sessions indefinitely, similar to how a chronic condition is managed long-term rather than cured outright. That decision gets revisited regularly between patient and prescriber rather than set once at the start of treatment.
How Clinicians Decide When to Stop or Continue
Continuing, adjusting, or stopping ketamine treatment is a judgment call built on a few recurring factors: how much symptom improvement shows up on standardized depression scales the clinic tracks session to session, how well a patient tolerates the dissociative and other side effects, how long relief holds between sessions once induction ends, and whether continued treatment still makes sense against its cost and time demands. A clinic that's tracking outcomes properly should be able to show you your own symptom trend over the series, not just tell you verbally that you're doing better.
Many clinics use standardized depression rating scales — the PHQ-9 or the MADRS are common examples — at intake and again at set points through the series to put a number on how symptoms are moving, rather than relying only on how a patient describes feeling in the moment. Asking a prospective clinic whether and how they track outcomes this way is a reasonable question, and a clinic that can't describe how it measures progress is worth a second look.
Side effects that don't settle with continued treatment, a plateau where sessions stop producing additional benefit, or a patient's own sense that the treatment isn't worth its burden relative to the relief it provides are all legitimate reasons to stop or change course. None of those outcomes mean the series failed as a concept — they're the normal range of how individualized treatment gets adjusted over time.
What If There's No Response Partway Through?
Many clinics check in around the third or fourth infusion of an induction series to gauge early response, since some patients show improvement well before the series ends while others take the full six sessions to show any change. A limited response at that checkpoint isn't automatically a reason to stop — it's a reason for a conversation with your prescriber about whether to continue as planned, adjust dosing, or consider extending the series before making a final call.
If a full induction series is completed with no meaningful improvement, that's useful clinical information rather than a dead end. Options a prescriber might discuss include switching between IV ketamine and Spravato, since some patients respond to one format and not the other, adjusting dose or infusion rate within the same format, or concluding that ketamine isn't the right treatment for this particular case and returning to other depression-treatment options. A single non-response doesn't rule out every ketamine-based approach, but it does mean the plan needs to change rather than repeat.
How Long Does Ketamine Work for Depression?
The honest answer is that it varies more than most patients expect going in. A single infusion or dose can produce improvement that peaks within days and fades within one to two weeks without follow-up treatment — which is exactly why induction series and maintenance dosing exist rather than a one-time session. After a completed induction series, some patients hold their improvement for a month or more between maintenance visits; others need more frequent boosters to stay stable. Neither pattern is unusual, and duration of response is one of the main variables prescribers track across a treatment course to plan how to space future sessions. For a longer look at what repeated ketamine use means for safety over months and years, rather than how long a single course's benefit lasts, see the long-term effects of ketamine therapy.
Cost Implications of Series Length
Session count directly drives cost, which is worth factoring in before committing to a plan. IV ketamine is usually self-pay, so a six-infusion induction series at a per-session price means the full series cost multiplies quickly, and any extension beyond the initial plan or ongoing maintenance boosters add to that total indefinitely. Spravato is more often covered by insurance with prior authorization, which changes the math substantially for patients who qualify for coverage, though copays across twice-weekly visits for a month still add up before stepping down to less frequent dosing. Before starting either option, it's worth asking a clinic directly what a full induction series costs, what maintenance sessions cost afterward, and whether pricing changes if the series runs longer than initially planned. A full breakdown of typical pricing across formats is covered in how much ketamine therapy costs.
To find providers offering IV ketamine, Spravato, or both near you, along with pricing when a clinic publishes it, browse ketamine clinics near you.
Frequently Asked Questions
How many ketamine treatments do you need for depression?
Most IV ketamine protocols for depression start with an induction series of around six infusions spread over two to three weeks. That number isn't universal — some clinics run shorter or longer series based on how a patient responds — but six is the count referenced most often in published research and clinic protocols. Spravato follows a different, FDA-labeled schedule: twice weekly for the first month. Confirm the exact plan with the clinic before starting, since protocols vary.
What is a typical ketamine dosing schedule for depression?
For IV ketamine, a common pattern is two to three infusions per week during the induction series, spaced out rather than given on consecutive days, followed by booster sessions every few weeks to a few months once a response is established. Spravato's labeled schedule is twice weekly for weeks one through four, then weekly for weeks five through eight, then weekly or every-other-week maintenance from week nine onward. Actual dosing decisions belong to the prescribing clinician managing your care.
How long does one course of ketamine treatment take?
A standard IV induction series usually runs two to three weeks from first infusion to last. Add evaluation and screening beforehand, and the full process from intake to finishing induction commonly spans three to five weeks. Spravato's induction-to-maintenance timeline is longer by design — about eight weeks before a patient reaches the less-frequent maintenance phase — because its schedule is fixed by the FDA label rather than adjusted session-by-session the way IV protocols often are.
How long does ketamine's effect last after a treatment course?
This varies considerably by patient. Some people notice symptom relief lasting weeks after completing an induction series; others find the effect fades faster and need closer-spaced maintenance sessions to sustain it. There's no fixed timeline that applies to everyone, which is exactly why maintenance dosing is individualized rather than scheduled on a single default calendar. Tracking how long relief lasts after each session is one of the main things a prescriber uses to plan your next visit.
What happens if ketamine isn't working partway through a series?
A clinician will typically evaluate you partway through the induction series, often around session three or four, to check for any response before committing to the full course. Limited or no improvement partway through doesn't automatically mean the series is stopped, since some patients respond later than others, but it's a checkpoint your provider should discuss with you rather than something to sit through silently. If a full induction series produces no meaningful change, that's real clinical information — it may mean adjusting dose, switching formats (IV to Spravato or vice versa), or considering a different treatment path entirely.
This guide describes common protocol patterns, not a prescription for your treatment. Session counts, dosing, and scheduling should always be confirmed directly with the clinic providing your care, and any change to your treatment plan should go through the clinician managing it.
Informational only — not medical advice. Protocols vary by clinic and by patient; treat the schedules described here as typical patterns to ask about, not a plan to follow on your own.